Back to results
US 2021/0061773 A1Published application
Compound and use thereof in medicine
AssigneeChangsha Hooz Bioscience And Technology Co., Ltd
InventorsXiong LI, Guojian XIE
Life of this patent
Estimating the term…
Abstract
Disclosed are a compound and a pharmaceutically acceptable salt thereof, which can be used, by means of a chemical small molecule which targets both UHFR1 and HDAC1, or a pharmaceutically acceptable salt thereof, as corresponding inhibitors or drugs for treating diseases, and are used for treating myelodysplastic syndrome, psoriasis, scar hyperplasia, prostate or breast hyperplasia, hematologic neoplasms and solid cancers alone or combined with other methods. Same have a good therapeutic effect.
Claims6
1:
- A compound and pharmaceutically acceptable salts thereof;
- the compound has the following formula:
- wherein n is selected from a positive integer from 1 to 7, and R is selected from one of the following substituents —H, —F, —Cl, —Br, —I, —NH2, —OH, —CN, —SH, —CF3, —CH3, —CH2CH3,
2:
- The compound and pharmaceutically acceptable salts thereof according to claim 1, wherein the compound has the following formula:
3:
- The compound and pharmaceutically acceptable salts thereof according to claim 1, wherein the pharmaceutically acceptable salts are:
- chloride, bromide, iodide, phosphate, sulfate, carbonate, bicarbonate, formate, acetate, propionate, benzoate, picolinate, fumarate, maleate, malate, succinate, methanesulfonate, tosylate, trifluoromethanesulfonate, tetrafluoroborate or hexafluorosulfte.
4:
- The compound and pharmaceutically acceptable salts thereof according to claim 2, wherein the pharmaceutically acceptable salts are:
- chloride bromide, iodide, phosphate, sulfate, carbonate, bicarbonate, formate, acetate, propionate benzoate picolinate, fumarate, maleate, malate, succinate, methanesulfonate tosylate, trifluoromethanesulfonate, tetrafluoroborate or hexafluorosulfte.
5:
- Use of the compound and pharmaceutically acceptable salts thereof as claimed in claim 1 in preparation of drugs treating myelodysolastic syndrome, psoriasis, scar hyperplasia, prostatic hyperplasia ductal hyperplasia, hematological tumors and solid cancers.
6:
- Use of the compound and pharmaceutically acceptable salts thereof as claimed in claim 1 in preparation of UHRF1 and/or HDAC1 inhibitors.